Joslin said that the J&J units – LifeScan, Animas and Calibra Medical – signed on as founding and advisory board members of the Joslin Institute for Technology Translation.
The group will be "focused on leveraging the potential of technology with the introduction of clinical solutions, decision support tools and the advancement of digital health to improve the lives of people with diabetes," according to Joslin.
"We are pleased to welcome the Johnson & Johnson Diabetes Solutions Companies as Founding Members of JITT. Their commitment to developing and offering meaningful products to improve diabetes care around the world makes them ideal contributors to JITT," Joslin president & CEO John Brooks III said in prepared remarks. "We look forward to working closely with them as well as with our other Founding Members to provide further insight to clinical solutions that will impact diabetes-related technologies and allow for further advancement of decision support tools as we make strides into digital health."
"Our vision is to create a world without limits for people with diabetes," LifeScan president Val Asbury said in a statement. "We are honored to join with the Joslin Institute for Technology Translation to further accelerate the development of innovative patient-centric solutions to improve diabetes care and outcomes."
"It is very exciting to have the Johnson & Johnson diabetes solutions companies on board," added Harry Mitchell, executive director of JITT, in a statement. "We look forward to collaborating with them on clinical solutions to improve patient care and utilizing their international presence to help JITT further its mission."